[Acute myeloblastic leukemia and hepatocellular carcinoma following Waldenström's macroglobulinemia].
A 54-year-old man was admitted to our hospital for precise examination of pancytopenia in October 1988. He had been cut off his left femur and irradiated because of osteosarcoma in 1954. After 30 years, he was diagnosed as Waldenström's macroglobulinemia. Melphalan had been given 2 mg daily for 19 months until August 1988, when it was discontinued due to pancytopenia. Peripheral blood showed Hb 6.6 g/dl, platelet 40 x 10(3)/microliters, and WBC 2000/microliters with 33% blasts. Bone marrow showed normocellularity with 36% blasts. Although blasts were negative for peroxidase staining, surface marker analysis revealed myeloid (CD 13, CD 33) phenotypes. Chromosome analysis showed 45, XY, -7, inv (3). A CT scan of the liver showed a mass, 10 by 10 cm, compatible with hepatocellular carcinoma. He was treated with very low dose Ara-C without noticeable effect. Hepatic tumor gradually enlarged, and he died of hepatic failure. This is a rare case of quadruplicate malignancies. The chromosomal abnormality suggests that AML was secondary leukemia which might be associated with immunosuppression due to macroglobulinemia and/or melphalan therapy.
Yamamoto
K
K
First Department of Internal Medicine, Tokyo Medical and Dental University.
Tohda
S
S
Miki
T
T
Suzuki
T
T
Nagata
K
K
Kamiyama
T
T
Miura
O
O
Imai
Y
Y
Murakami
N
N
Katoh
A
A
D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D005266:Femoral Neoplasms / Q000473:pathology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000473:pathology*; D008113:Liver Neoplasms / Q000473:pathology*; D008297:Male; D008558:Melphalan / Q000009:adverse effects; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary; D012516:Osteosarcoma / Q000473:pathology; D008258:Waldenstrom Macroglobulinemia / Q000150:complications* / Q000188:drug therapy
D008558:Melphalan